What GLP-1 Drugs Actually Cost in the UAE Right Now

Walk into a Dubai pharmacy asking for Ozempic and you will likely be told the same thing patients hear in the United States: it depends on what is in stock this month. The UAE has among the highest rates of diabetes and obesity in the world, which makes GLP-1 receptor agonists more relevant here than almost anywhere else. It also means demand keeps colliding with limited supply.

Here is where things actually stand for patients trying to access these drugs through licensed channels in the Gulf.

Why demand is so high in the region

Diabetes prevalence in the UAE has been documented as one of the highest in the world, with a 2011 figure of 19 percent later reinforced by more recent International Diabetes Federation data placing UAE prevalence around 17.3 percent, according to a review on the diabetes epidemic sweeping the Arab world. Obesity figures compiled by WHO and cited in regional research put overweight prevalence at roughly 70 percent in both women and men in the UAE, with obesity itself affecting around 41 percent of women and 32 percent of men, per data referenced in the UAE National Diabetes and Lifestyle Study. Saudi Arabia sits in a similar bracket, ranked among the ten countries with the highest diabetes prevalence globally, with IDF estimates putting the figure at 20.8 percent by 2030, according to a Saudi Medical Journal review of diabetes across Gulf Cooperation Council countries.

What these drugs cost in the UAE

Ozempic pricing in the UAE runs from roughly AED 744 to AED 1,200 per month depending on dose, with the entry 0.25 mg starting dose priced from around AED 744, according to pricing data compiled by MedX Pharmacy. Mounjaro is priced differently, with reporting indicating a single unified price of AED 1,734 per pen regardless of the 2.5 mg through 15 mg dose strength, though other pharmacy listings show a broader range, roughly AED 1,500 to AED 2,600, depending on dosage and pharmacy, according to figures gathered by a Gulf medication pricing overview.

Why shortages keep happening here too

The same supply strain hitting Western markets has reached the Gulf. Reporting from Burjeel describes how high off-label demand for diabetes drugs being used for weight loss has directly contributed to shortages in the UAE market, echoing the pattern seen with Ozempic supply constraints internationally.

Insurance rarely covers weight loss use

UAE medical insurance policies generally do not cover GLP-1 prescriptions when the indication is weight loss rather than diagnosed type 2 diabetes, meaning most patients pursuing these drugs for obesity management are paying the full pharmacy price out of pocket. That gap in coverage is a major reason cost comparisons between Ozempic, Wegovy and Mounjaro matter so much to patients here, more so than in markets with broader insurance coverage for obesity treatment.

Whether prices are trending down

Regional coverage from Gulf News has tracked whether Ozempic, Wegovy and Mounjaro prices are moving in a more affordable direction as more manufacturers and formulations, including oral options, reach the market. There is no single settled answer. Prices vary by pharmacy, dose and ongoing supply conditions rather than following one clean downward trend.

This article reports on pricing and prevalence data available at time of publication and is not medical advice. Cost, prescription eligibility, and whether a GLP-1 receptor agonist is appropriate for weight management or diabetes control in a specific patient are decisions to make with a licensed physician in the UAE or Saudi Arabia, not from a price list alone.

With demand unlikely to ease and new drugs such as tirzepatide and eventually retatrutide expanding the options available, price and availability, not the underlying biology, may end up being the biggest factor shaping who in the Gulf actually gets access to this drug class.